State Law To Stop Insurance Redlining Of Mental Illness

17 February 1997

A state-wide coalition in Illinois, USA, has proposed legislation to endhealth insurance discrimination against severe mental illness. Valerie Raskin, president-elect of the Illinois Psychiatric Society, which is backing House Bill 111, says: "there's no medical justification to cover illness such as diabetes, asthma, heart disease or cancer and refuse to cover serious mental illness."

Many mental disorders involve a chemical imbalance in the brain which modern medicine can treat effectively, said Dr Raskin. The success rate for clinical depression is 85%, and for panic disorder and bipolar (manic-depressive) illness it is 80%. In contrast, improvement rates produced by common heart treatments, such as angioplasty and atherectomy, are only 41% and 52%.

The coalition says that other states, such as Maryland and Texas, have shown that equitable coverage is not expensive and reduces other costs such as emergency room visits. It also notes that a state poll conducted late last year found that 69% of Illinois voters believe that insurance companies discriminate against the mentally ill, and 88% said they would favor a state law that would "require insurance companies to provide equal coverage between mental and other medical illnesses."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight